This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Oxycodone, sold under the brand names Roxicodone and OxyContin (which is the extended-release form) among others, is a semi-synthetic opioid used medically for the treatment of moderate to severe pain. It is a highly addictive and commonly abused drug. It is usually taken orally, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin. Common side effects include euphoria, constipation, nausea, vomiting, loss of appetite, drowsiness, dizziness, itching, dry mouth, and sweating. Side effects may also include addiction and dependence, substance abuse, irritability, depression or mania, delirium, hallucinations, hypoventilation, gastroparesis, bradycardia, and hypotension. Those allergic to codeine may also be allergic to oxycodone. Opioid withdrawal may occur if rapidly stopped. Oxycodone acts by activating the μ-opioid receptor. When taken by mouth, it has roughly 1.5 times the effect of the equivalent amount of morphine. Oxycodone was originally produced from the opium poppy opiate alkaloid thebaine in 1916 in Germany. One year later, it was used medically for the first time in Germany. Oxycodone is available as a generic medication. In 2023, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.
patients with active hepatic disease patients in whom spasticity is utilized to maintain upright posture and balance patients with a hypersensitivity to dantrolene There are no contraindications for intravenous dantrolene used for prophylaxis or management of malignant hyperthermia.
The Captagon was all destroyed by the new government; "Khattab", a pseudonym of one of the former rebels said "We destroyed and burned it because it's harmful to people. It harms nature and people and humans." The New York Times reported in December 2021 that the Syrian Army's elite 4th Armoured Division, commanded by Maher al-Assad, the brother of Syrian President Bashar al-Assad, oversaw much of the production and distribution of fenethylline, among other drugs. The unit controlled manufacturing facilities, packing plants, and smuggling networks all across Syria, and had started to deal in crystal meth. The division's security bureau, headed by Maj. Gen. Ghassan Bilal, provided protection for factories and along smuggling routes to the port city Latakia and to border crossings with Jordan and Lebanon. Jihad Yazigi, editor of The Syria Report, reported that fenethylline had "probably become Syria's most important source of foreign currency."
Sources: en.wikipedia.org
Recently, the MMP3 gene was shown to be down-regulated in individuals with cleft lip and palate when compared to controls, reinforcing the nature of cleft lip/palate as a condition resulting from insufficient or defective embryonic tissue remodeling.
The Healthcare Facilities Accreditation Program (HFAP) is a not-for-profit organization meant to help healthcare organizations maintain their standards in patient care and comply with regulations and the healthcare environment. Headquartered in Chicago, HFAP is an accreditation organization with authority from Centers for Medicare and Medicaid Services. HFAP provides accreditation programs for hospitals, clinical laboratories, ambulatory surgical centers, office based surgery, and critical access hospitals. HFAP also accredits mental health and physical rehabilitation facilities and provides certification for primary stroke centers. HFAP was founded in 1943 by the American Osteopathic Association, a medical organization representing osteopathic physicians.
=== Second House passage === The House of Representatives needed to pass the Senate version of the OBBBA for the bill to reach the President's desk. On July 1, 2025, President Trump and Senate majority leader Thune expressed confidence that the bill would pass in the House. House Republican moderates such as David Valadao and Young Kim of California, and Jeff Van Drew of New Jersey, who are against Medicaid cuts, Nick LaLota of New York, who is against SALT changes, and fiscal conservatives such as Chip Roy and Keith Self of Texas, who oppose federal deficit increases, had expressed opposition by June 30 to the bill in its then-current form. The House Rules Committee voted 7–6 on July 1, 2025, to advance the bill to the floor. Fiscal conservative Republicans Chip Roy and Ralph Norman voted against advancing the bill. Usually, the members of the majority party on the Rules Committee always vote to advance the bill to the floor. A procedural vote on July 2, 2025, while negotiations were ongoing off the House floor, was the longest vote in House history. In the early morning of July 3, 2025, the House approved the final procedural rule vote 219–213. The vote, which began on the evening of July 2, was initially opposed by five Republicans: moderate Brian Fitzpatrick of Pennsylvania and fiscal conservatives Victoria Spartz of Indiana, Andrew Clyde of Georgia, Keith Self of Texas, and Thomas Massie of Kentucky. Eight other fiscal conservative Republicans, including Tim Burchett of Tennessee and Chip Roy of Texas, withheld their votes.
Sources: en.wikipedia.org
== Safety considerations == Because microbial therapeutics involve living organisms, safety is a key consideration in their development and use. Potential risks include uncontrolled growth of the microorganisms, unwanted interactions with the existing microbiome, or unexpected immune reactions. There are also concerns about the transfer of genetic material between microorganisms, which could affect other microbes in the body or the environment. To reduce these risks, researchers use multiple safety strategies. One approach is biocontainment, which involves designing microorganisms so they can survive only under specific conditions. For example, engineered microbes may depend on nutrients that are only available during treatment or be programmed to self-destruct after a certain period of time. These strategies help limit how long the microorganisms persist and reduce the risk of unintended spread. Additional safety measures include careful selection of microbial strains, extensive testing in laboratory and animal studies, and controlled clinical trials in humans. Regulatory agencies require thorough safety evaluations before microbial therapeutics can be approved for clinical use, with the goal of ensuring that these treatments are both effective and safe.
The largest man-made sources of carbonyl sulfide release include its primary use as a chemical intermediate and as a byproduct of carbon disulfide production; however, it is also released from automobiles and their tire wear, coal-fired power plants, coking ovens, biomass combustion, fish processing, combustion of refuse and plastics, petroleum manufacture, and manufacture of synthetic fibers, starch, and rubber. The average total worldwide release of carbonyl sulfide to the atmosphere has been estimated at about 3 million tons per year, of which less than one third was related to human activity. It is also a significant sulfur-containing impurity in many fuel gases such as synthesis gas, which are produced from sulfur-containing feedstocks. Carbonyl sulfide is present in foodstuffs, such as cheese and prepared vegetables of the cabbage family. Traces of COS are naturally present in grains and seeds in the range of 0.05–0.1 mg/kg. Carbonyl sulfide has been observed in the interstellar medium (see also List of molecules in interstellar space), in comet 67P and in the atmosphere of Venus, where, because of the difficulty of producing COS inorganically, it is considered a possible indicator of life.
A broader survey of Drosophila de novo proteins likewise found that most differ from conserved proteins in predicted properties, but that a subset are predicted to adopt known folds and participate in specific cellular processes. Inference from prediction tools requires caution because many predictors were trained and benchmarked primarily on conserved, globular proteins, and their performance can be biased for short or low-homology sequences. In particular, disorder predictions can be sensitive to parameter choices, and different structure predictors (including alignment-based and protein language model approaches) may disagree on de novo proteins and yield low-confidence models. Comparisons of "newly born" orphan proteins to "never born" random polypeptides using multiple deep-learning structure predictors similarly reported that predicted models are often of low quality while still allowing limited qualitative comparisons across sequence sets.
suborder Clypeasterina family Clypeasteridae L. Agassiz, 1835 family Fossulasteridae Philip & Foster, 1971 † family Scutellinoididae Irwin, 1995 † family Conoclypeidae von Zittel, 1879 † family Faujasiidae Lambert, 1905 † family Oligopygidae Duncan, 1889 † family Plesiolampadidae Lambert, 1905 † suborder Scutellina infraorder Laganiformes family Echinocyamidae Lambert & Thiéry, 1914 family Fibulariidae Gray, 1855 family Laganidae Desor, 1858 infraorder Scutelliformes family Echinarachniidae Lambert in Lambert & Thiéry, 1914 family Eoscutellidae Durham, 1955 † family Protoscutellidae Durham, 1955 † family Rotulidae Gray, 1855 superfamily Scutelloidea Gray, 1825 family Abertellidae Durham, 1955 † family Astriclypeidae Stefanini, 1912 family Dendrasteridae Lambert, 1900 -- Pacific eccentric sand dollar. family Mellitidae Stefanini, 1912 -- Keyhole sand dollars family Monophorasteridae Lahille, 1896 † family Scutasteridae Durham, 1955 † family Scutellidae Gray, 1825 family Taiwanasteridae Wang, 1984 family Scutellinidae Pomel, 1888a † However, the traditional Clypeasteroida is currently not thought to represent a monophyletic group because the Clypeasterina and Scutellina are most likely not each other's closest relatives. Their similarities are possibly the result of convergent evolution. They are part of clade Luminacea, which also includes the orders Cassiduloida and Echinolampadoida. In a recent classification, Clypeasteroida includes only the former Clypeasterina.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.